|
Feb 14
|
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
|
|
Feb 10
|
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
|
|
Feb 10
|
Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company
|